These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 16266195)

  • 1. Docetaxel in hormone-refractory metastatic prostate cancer.
    McKeage K; Keam SJ
    Drugs; 2005; 65(16):2287-94; discussion 2295-7. PubMed ID: 16266195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which drug combination for hormone-refractory prostate cancer?
    Doggrell SA
    Expert Opin Pharmacother; 2005 Apr; 6(4):667-70. PubMed ID: 15934892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
    Font A; Murias A; Arroyo FR; Martin C; Areal J; Sanchez JJ; Santiago JA; Constenla M; Saladie JM; Rosell R
    Ann Oncol; 2005 Mar; 16(3):419-24. PubMed ID: 15668260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP
    Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
    Tannock IF; de Wit R; Berry WR; Horti J; Pluzanska A; Chi KN; Oudard S; Théodore C; James ND; Turesson I; Rosenthal MA; Eisenberger MA;
    N Engl J Med; 2004 Oct; 351(15):1502-12. PubMed ID: 15470213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxetaxel: new indication. Prostate cancer: a few more weeks.
    Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
    Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R
    Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
    BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].
    Ferrero JM
    Bull Cancer; 2005 May; 92(5):425-7. PubMed ID: 15932803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
    Tester W; Ackler J; Tijani L; Leighton J
    Cancer J; 2006; 12(4):299-304. PubMed ID: 16925974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
    Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
    Collins R; Fenwick E; Trowman R; Perard R; Norman G; Light K; Birtle A; Palmer S; Riemsma R
    Health Technol Assess; 2007 Jan; 11(2):iii-iv, xv-xviii, 1-179. PubMed ID: 17181985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.